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This workshop was held on July 31-August 1, 2010 and was organized to promote the academic environment and to 
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Gynaecologic Oncologists (ASGO), which will be held on November 3-5, 2011. We summarized the whole contents 
presented at the workshop. Regarding cervical cancer screening in Asia, particularly in low resource settings, and an 
update on human papillomavirus (HPV) vaccination was described for prevention and radical surgery overview, 
fertility sparing and less radical surgery, nerve sparing radical surgery and primary chemoradiotherapy in locally 
advanced cervical cancer, were discussed for management. As to surgical techniques, nerve sparing radical 
hysterectomy, optimal staging in early ovarian cancer, laparoscopic radical hysterectomy, one-port surgery and robotic 
surgery were introduced. After three topics of endometrial cancer, laparoscopic surgery versus open surgery, role of 
lymphadenectomy and fertility sparing treatment, there was a special additional time for clinical trials in Asia. Finally, 
chemotherapy including neo-adjuvant chemotherapy, optimal surgical management, and the basis of targeted therapy 
in ovarian cancer were presented.
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PREVENTION OF CERVICAL CANCER
1. Cervical cancer screening in Asia, Mohamad Farid Aziz
Cervical cancer is the third most common cancer in women, 
and the seventh overall, with an estimated 529,000 new cases 
in 2008. More than 85% of the global burden occurs in devel-
oping countries, where it accounts for 13% of all female 
cancers.1 
Southeastern Asia are less developed regions, the estimated 
age-standardized incidence and mortality rates per 100,000 
are higher than those of Eastern Asia. Thailand has the high-
est incidence and mortality among the southeastern coun-
tries, while Singapore is the lowest. In Eastern countries, 
Hong Kong is the lowest in incidence. Prevalence of human 
papillomavirus (HPV) infection is slightly different, but HPV 
16 is consistent in southeastern and eastern Asia. Contribut-
ing factors to the development of cervical cancer in general are 
young age at first intercourse, high parity, and multiple sexual 
partners. Cervical cancer screening programs that are fully 
supported by their governments in these regions are very few, 
especially in the Southeastern regions. The methods are Pap 
smear, colposcopy, and in less developed countries, visual in-
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spection with acetic acid followed by cryotherapy is more 
favored. The last procedure is known as “See and Treat.” 
Targeted age-groups and interval of screening are slightly dif-
ferent in each country.
2. Screening in low resource setting, Uma K. Devi
Cervical cancer is the most common cancer among women in 
developing countries. Cervical cancer accounted for 493,000 
newly diagnosed cases, 1.4 million prevalent cases and 
273,000 deaths worldwide in the year 2002. Of these, more 
than 80% occurred in the low- and medium-resource coun-
tries in South & Southeast Asia, Sub-Saharan Africa, and 
South & Central America.2 Unfortunately, these low resource 
countries have access to less than 5% of the global cancer 
treatment resources.3 Estimated age-adjusted mortality rates 
due to cancer of the uterine cervix exceed 10 per 100,000 
women in most developing countries, with rates exceeding 25 
per 100,000 in East African countries, as opposed to less than 
5 per 100,000 women in most developed countries.
The purpose of cervical cancer screening is to decrease the 
morbidity and mortality associated with a specific disease 
through early detection. This aim is achieved through the per-
formance of cost effective tests applied to an asymptomatic 
population that is at significant risk for the disease. Cytology 
screening has been largely responsible for the significant de-
cline in the burden of cervical cancer in developed countries in 
the last five decades, and has reduced invasive cervical cancer 
rates by 74%. 
The Pap test is yet to be effectively implemented in many de-
veloping countries, or has failed to reduce cervical cancer bur-
den to an appreciable extent in some developing countries. 
The apparent lack of impact of cervical cytology program and 
difficulties in organizing such programs in low- and medium- 
resource countries have prompted the search for and evalua-
tion of alternative screening tests and paradigms that require 
one single or two visits, to complete the screening and diag-
nosis/treatment processes. However, WHO has suggested 
low intensity cytology/Pap test once a lifetime after 35 years 
at 10 year intervals, and simple visual inspection of the cervix 
to organize cytology for the control of cervical cancer in devel-
oping countries. As this method of visual inspection did not 
detect microscopic disease, it was considered inadequate.4-6
Hence, various strategies have been devised as an alternative 
to appropriate technologies in cervical cancer screening for low 
resource settings, for example, visual inspection with acetic 
acid (VIA),7,8 visual inspection with Lugol’s iodine (VILI), com-
bination of VIA and VILI, cervicography, “See & Treat” techni-
ques using diathermy, cryosurgery, and the HPV test.9-11
Although the sensitivity of VIA ranged between 66% and 
96%, and specificity between 64% and 98% in a low resource 
setting, it is difficult to ensure screening at regular intervals, 
so a single screening test will be a good option, or a HPV test 
at a ten year interval is another alternative proposal. 
In conclusion, attempts to screen in low resource settings 
have yet to determine the optimal screening strategy, or to 
demonstrate a significant reduction in mortality due to these 
efforts. The impact of future screening strategy at low re-
source settings require further exploration, and until then 
VIA and HPV testing may be considered as another option. 
3. Update on HPV vaccination, Hextan Y. S. Ngan
Cervical cancer vaccines are prophylactic vaccines prevent-
ing infection of HPV types 16 and 18 which are associated 
with about 70% of cervical cancer worldwide. So far, 100% 
and more than 90% efficacy in preventing CIN2/3 was shown 
by both the bivalent and quadrivalent vaccines in their phase 
II and III studies, respectively.12,13 Also, a decrease in abnor-
mal cytology, need for colposcopy referral or treatment were 
shown in the phase III trial. No excessive serious adverse 
events over controls were seen in both vaccines. Post-market-
ing surveillance showed that for both vaccines were safe. 
Several issues arise on further analysis of trial data or new 
trials which showed there was evidence of cross-protection to 
other non-targeted HPV types; the apparent waning of anti-
body levels in HPV 18 in the quadrivalent vaccine, the anti-
body assay using the same method on both vaccines, efficacy 
in adult women, and apparent efficacy in women previously 
infected by HPV.
Sub-group analysis showed 68-70% efficacy in preventing 
CIN caused by HPV 31 for both vaccines, and almost 100% for 
HPV 45 in bivalent vaccines. Since the trial was not powered 
or designed for assessment of efficacy to non HPV 16 and 18, 
these results had to be interpreted with care. Since the pro-
tection is not complete and the duration of protection is yet to 
be determined, the exact benefit of cross-protection is diffi-
cult to define. However, the theoretical advantage of sig-
nificant prevention of HPV 45 is in the prevention of ad-
enocarcinoma, which is not easy to detect by conventional cy-
tology screening. A properly designed randomized control tri-
al is needed to determine the impact of cross-protection on 
adenocarcinoma. The new development of multivalent vac-
cines may provide more protection than the current vaccines.
Long term follow-up of antibody levels for HPV 16 and 18 af-
ter 8.4 years still showed more than 10- fold levels above the 
baseline in the bivalent vaccine.14 For the monovalent HPV16 
vaccine, high levels were seen after more than 9 years. While 
the antibody of HPV18 seems to have declined to the level of 
natural infection in the quadrivalent vaccine, it could be due to 
the method of assay based on one epitope only. One study us-
ing same method, pseudovirion-based neutralizing assay, in 
monitoring antibody levels showed significantly higher anti-
body levels after bivalent than quadrivalent vaccines, which 
may be due to the new adjuvant ASO4 in the bivalent 
vaccine.15 However, both vaccines showed substantially high 
levels of antibody response over natural infection. Based on 
mathematical models of the decline of the antibody over the 
years, boosters may not be needed for at least 20 years. 
Since registration data was based on efficacy trials in 16-26 
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years of age and bridging immunological response study of 
adolescence, efficacy on adult women was performed for data 
in supporting registration up to 45 years of age.12,16 The quad-
rivalent vaccine trial in 24-45 year old women showed 83% ef-
ficacy in preventing persistent infection, CIN or external geni-
tal lesion (EGL).17 The bivalent vaccine trial in women 24-45 
years showed efficacy in preventing persistent infection. Both 
studies showed no increase in SAE. Thus, vaccinating adult 
women is effective and safe.
In the sub-group analysis, women who were HPV negative 
but seropositive showed significantly lower persistent in-
fection and CIN rates in the vaccinated arm when compared to 
the control arm.18 Though again this observation was not in 
the original design of the trial, the high antibody response af-
ter vaccination in previously infected women with a low natu-
ral infection antibody titre seems to be effective in preventing 
HPV re-infection.12 Though the incidence of infection is de-
creasing with increasing age, new infections were still found 
in older women and these women may benefit from vaccine 
protection. Furthermore, recent epidemiology studies showed 
that in some regions of the world, a second peak of HPV in-
fection was found in women, suggesting that there is certain 
benefit in vaccinating sexually active adult women.19 However, 
it is difficult to predict the degree of protection in these 
women.
To conclude, evidence so far showed that both the bivalent 
and quadrivalent vaccines are effective and safe and should be 
considered for population vaccination of girls/adolescence 
before sexual exposure. Vaccination of adult women may have 
some benefits that need individual counseling. Cervical can-
cer screening is still required as the protection after vacci-
nation is not complete.
NEW TRENDS IN CERVICAL CANCER MANAGEMENT
1. Radical surgery overview, Jong Hyeok Kim/Joo-Hyun 
Nam
Radical hysterectomy is a well established standard surgical 
management for early stage cervical cancer. This operation 
yields 5-year survival rates of 75-90% in most cases. After its 
introduction in the management of early stage cervical cancer 
over 100 years ago, surgical technique, anatomic detail, and 
classification of this surgery are continuously evolving. 
For the first time, Sharma et al.20 introduced radical extir-
pation of the parametria with a vaginal approach in the manage-
ment of early stage cervical cancer. And then, Wertheim devel-
oped the abdominal radical hysterectomy, and this led to the 
near abandonment of the vaginal radical hysterectomy.20 
However, the mortality rate after abdominal radical hyster-
ectomy was as high as 40% at that time. Therefore, the use of 
abdominal radical hysterectomy decreased with the intro-
duction of radiation therapy in the management of cervical 
cancer.
In the 1940s, Meigs reintroduced the Wertheim’s abdominal 
radical hysterectomy, combining it with complete pelvic 
lymph node dissection to increase its therapeutic efficacy. In 
addition, the advances in antibiotics, anesthetic techniques, 
and surgical techniques reduced morbidity and mortality as-
sociated with abdominal radical hysterectomy to acceptable 
levels. Therefore, the Meigs procedure became the standard of 
care in western countries. 
Besides the Meigs procedure, the Wertheim’s operation has 
been modified many times by several surgeons to improve 
both anatomic detail and radicality. Among them, Okabayahi 
in Japan sought to improve the technique by developing a 
more radical removal of tissue than advocated by Wertheim. 
Okabayashi’s method is characterized by wide extirpation of 
parametrial tissue and a rather novel separation of the posteri-
or leaf of the vesicouterine ligament. The techniques em-
ployed, and the results of Okabayashi’s radical hysterectomy, 
were first reported in 1921, and this method became standard 
for radical hysterectomy in Japan.21 In the 1950s, Mitra used 
an extraperitoneal pelvic lymph node dissection, and Dargent 
introduced laparoscopic pelvic lymph node dissection in com-
bination with radical vaginal hysterectomy, and this made 
vaginal radical hysterectomy to be looked at with renewed 
interest. Recently, with the advances in the laparoscopic sur-
gical techniques and instruments, total laparoscopic radical 
hysterectomy has been a minimally invasive alternative to the 
abdominal radical hysterectomy.20 Robotic radical hyster-
ectomy is more widely accepted in the management of early 
stage cervical cancer. Other recent advances in the surgical 
management of early stage cervical cancer include nerve-sparing 
radical hysterectomy and fertility-sparing radical trachelec-
tomy.22 The major merit of these operations is to improve the 
functional outcome and quality of life. 
2. Fertility sparing and less radical surgery, Seung Cheol 
Kim
In the past, a diagnosis of early stage invasive cervical cancer 
would usually lead to infertility because of the recommended 
treatment, a radical hysterectomy with bilateral pelvic lym-
phadenectomy for stage IA2-IB1 cervical cancer. This some-
times includes radiation therapy and/or chemotherapy. Over 
the past decade, there has been an increased focus towards 
fertility preservation in the treatment of cervical cancer, since 
about 15% of all cervical cancers and 45% of surgically treated 
stage IB cancers occur in women under 40 years of age. These 
women represent the subset of patients who are candidates 
for fertility preservation if they are identified as having a low 
risk of recurrence and a low risk of lymph-node involvement. 
The majority of experience with fertility sparing in cervical 
cancer has been with radical vaginal trachelectomies (RVT). 
RVT with laparoscopic pelvic lymphadenectomy is a fertil-
ity-preserving procedure that has recently gained worldwide 
acceptance as a method of surgically treating small invasive 
cancers of the cervix.23 Since the original description of RVT 
by Daniel Dargent in 1994, over 500 cases of utilization of this 
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technique have been reported in the literature, with over 100 
live births reported following this procedure. The morbidity 
associated with RVT is low, with a tumor recurrence rate of 
5% and a mortality rate of 3%.24 The current literature in-
dicates no difference in the rate of recurrence with this techni-
que compared with radical hysterectomy, when proper se-
lection criteria are used. In Korea, there is a recent study 
showing that laparoscopic radical trachelectomy is a safe and 
useful alternative to radical hysterectomy by Kim et al.25 in 
2010. 
The radical abdominal trachelectomy (RAT) is very similar 
to the radical hysterectomy (RH), making it a more accessible 
procedure for surgeons trained in radical pelvic surgery. 
Experience with RAT has been limited in comparison to RVT, 
but does offer another fertility-sparing option for young wom-
en with cervical cancer.26 The similar approach of this techni-
que to RH makes it more accessible to surgeons who are not 
well trained with radical vaginal surgery, and additionally can 
be used with larger tumors, or with vaginal anatomy that pro-
hibits the applicability of the RVT.27
Neoadjuvant chemotherapy (NACT) can reduce the tumor 
size prior to fertility-sparing surgery.28 NACT combined with 
conization and pelvic lymphadenectomy has also led to suc-
cessful pregnancies. It should be noted that alkylating agents 
such as ifosfamide and cisplatin may be detrimental to ovarian 
follicles, and less gonadotoxic regimens should be evaluated 
in the future. Approximately 65% of patients do not have any 
residual cancer in the trachelectomy specimen after a diag-
nostic cone. Additionally, the rate of parametrial involvement 
in patients with tumor size ≤2 cm, negative pelvic nodes, and 
depth of invasion ≤10 mm is only 0.6%.29 This highlights the 
question as to whether less aggressive surgery provides sim-
ilar effectiveness to RVT. Large conization or simple trache-
lectomy with pelvic lymphadenectomy might be an alter-
native for early stage low volume disease. The use of simple 
trachelectomy or cone biopsies for fertility sparing also war-
rants further investigation, which can be combined with 
NACT, as previously described. This will obviously require 
strict selection criteria to avoid recurrences and deaths in this 
group of highly curable patients.
The treatment of cervical cancer has evolved over the past 10 
years, with gradual abandonment of radical surgery in favor of 
more conservative techniques for young women wishing to 
preserve fertility. RVT is now well established as a safe a fea-
sible procedure for this patient population, with low morbid-
ity, recurrence, and mortality rates.30 As more experience 
with this procedure help to further delineate patient selection 
criteria and prognostic factors for adjuvant treatment, other 
additional fertility-sparing options continue to evolve. The 
use of RAT in selected patients has increased, in addition to 
more conservative methods of fertility sparing such as simple 
trachelectomy or cone biopsy, with or without NACT. 
Continued research in these areas will determine the safety 
and feasibility of these potential procedures, which will help 
give more treatment options for young women with early 
stage cervical cancers. 
3. Myths and facts about nerve-sparing radical hysterec-
tomy, Tomoyasu Kato
Autonomic nerve damage during surgery is thought to play 
a crucial role in the etiology of bladder dysfunction, sexual 
dysfunction, and colorectal motility disorders that are seen in 
patients after radical hysterectomy.31 Though it is only recent 
that nerve-sparing radical hysterectomy has been introduced 
to western as well as to Asian countries, the concept of preser-
vation of autonomic nerves during radical hysterectomy has 
now become the standard in many onco-gynecological centers 
in the world.
Pelvic organ function is organized by both the central and pe-
ripheral nervous system. For instance, the lower urinary tract 
is innervated by 3 sets of peripheral nerves involving the para-
sympathetic nerves from the sacral plexus, sympathetic 
nerves from the lumbar plexus, and somatic nervous systems 
such as the pudendal nerves. These nerves contain afferent 
sensory as well as efferent motor axons. Multiple reflex path-
ways organized in the brain and spinal cord mediate coordina-
tion between the urinary bladder and urethra. 
These autonomic nerves can be dissected during the differ-
ent phases of radical hysterectomy.22 A level of nerve preser-
vation is classified into 4 levels: non-touch, exposure, partial 
preservation, and dissection. From a point of view on nerve 
preservation, non-touch preservation provides a high quality 
of life. Simple and modified radical hysterectomy may obtain 
non-touch preservation of autonomic nerves, however they 
compromise radicality. To achieve a good balance between 
radicality and retaining pelvic function, we perform exposure 
or partial preservation of these autonomic nerves as follows:
1) Preserving the hypogastric nerves (HGN)
Developing the pararectal space between the ureter and the 
internal iliac vessels, HGN running along the rectum is to be 
identified. The ureter is separated from the retroperitoneum 
and this tissue plane is kept facing downwards. This tissue 
plane corresponds to the anterior renal fascia, which includes 
the HGN and the pelvic plexus (PP). 
2) Preserving the parasympathetic nerve (PSN)
The cardinal ligament (CL) is dissected immediately above 
the middle rectal artery as close as possible to the pelvic 
sidewall. The PSN originating from S3 run to the PP dorsal to 
the middle rectal artery.
3) Preserving the pelvic plexus (PP)
The HGN entered the PP at the anterosuperior corner. The 
deep uterine vein is located below the HGN. The HGN and the 
PP were frequently damaged during dissection of the utero-
sacral ligaments (USL). To diminish these nerve injuries, the 
medial stump of the CL should be fully mobilized above the 
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HGN before dissecting the USL. In case of a tumor with deep 
myometrial or parametrial invasion, we dissect the USL just 
below the medial stump of the CL. Then the PP is preserved 
partially.
4) Preserving the bladder branches
The bladder branches ventral to the ureter are more likely to 
be injured during dissection of the posterior leaf of the ves-
icouterine ligament for wide resection of the paracolpium and 
the vagina. In order to maximize preservation of the bladder 
branches dorsal to the ureter, the rectovaginal ligaments 
should be clamped using right angle forceps not to involve 
them and be cut. 
Through our method, even patients with partial preserva-
tion showed recovery to a postvoid residual urine volume less 
than 50 mL at a median of 24 days postoperatively.
Autonomic nerves are vulnerable to damage due to pressure 
from surgical retarctors, extension stress with taping, thermal 
injury by an energy source and/or direct injury with electrical 
scarpels. Both an understanding of the precise neuroanatomy 
and a gentle handling of the autonomic nerves are important 
to obtain a good balance between oncologic outcome and 
quality of life (QOL) after nerve-sparing radical hysterectomy.
4. Primary CCRT in locally advanced cervical cancer, Hee 
Sug Ryu
While radiotherapy has been established as the primary 
mode of therapy, it has been shown that radiotherapy alone is 
accompanied by a high failure rate in patients with large-sized 
lesions, or in patients at risk for recurrent disease after surgi-
cal treatment. These findings have led to the development of 
combination radiotherapy and chemotherapy, the presently 
widely employed concurrent chemoradiotherapy (CCRT). 
After Fu32 proposed the enhanced effect of the radiotherapy 
acting as a radiosensitizer, and the systemic effect of preventing 
distant metastasis of the cervical cancer, the results of 5 rando-
mized prospective studies regarding the role of CCRT in cer-
vical cancer patients were published between 1999 and 2000, 
and all 5 studies showed that platinum-based (cisplatin) CCRT 
decreased local and distant metastasis rates, and thus increased 
survival by 30% to 50%. It was also concluded that CCRT in-
creased survival by approximately 40% compared to radio-
therapy alone.33-36
Since then, CCRT has become the mainstay treatment mo-
dality for all cervical cancer patients requiring radiotherapy, 
and CCRT is provided largely for the following two groups of 
patients: 1) primary CCRT without surgery for patients with 
large-sized stage Ib tumors and stage IIb-IVa locally advanced 
disease, and 2) postoperative adjuvant CCRT for patients at 
high risk of treatment failure after radical hysterectomy. 
In 2007, regarding the efficacy of CCRT for the controversy 
of the treatment of stage Ib2 cervical cancer, the results of a 
multicenter study which was performed by the Korean 
Gynecology Oncology Group (KGOG) was published, which 
retrospectively investigated the survival rates of various 
modes of therapy for stage Ib2 cervical cancer patients during 
the past 10 years in Korea.37 This report concluded that sur-
vival rates were the best among patients who underwent post-
operative adjuvant CCRT, while the worst in radiotherapy 
only. Since 2005, the KGOG has been conducting a pro-
spective study in an attempt to ascertain the effectiveness of 
paclitaxel and carboplatin as a CCRT regimen for patients 
with high risk factors for recurrent disease after radical 
hysterectomy. We have to wait until the study will mature.
We have found in this review that CCRT is a widely used reg-
imen in the treatment of patients with cervical cancer, and 
that it is effective. While combination chemotherapy is asso-
ciated with increased toxicity, the toxicities are generally easi-
ly manageable. The weekly regimen containing cisplatin was 
associated with the least toxicity of all the regimens reviewed. 
We did not find any significant difference in disease free sur-
vival between the weekly and monthly chemotherapy regi-
mens for locoregionally advanced stage IIb-Iva cervical cancer, 
but there was a tendency for improved survival in patients 
who received monthly chemotherapy.
SURGICAL TECHNIQUE
1. Nerve sparing radical hysterectomy, Shingo Fujii
Since Ernst Wertheim introduced radical hysterectomy in 
1911, several different types of modifications have been made 
on radical hysterectomy. In western countries, radical hyster-
ectomy classified by Piver, Rutledge and Smith as the class III 
is believed as the standard procedure of radical hysterectomy. 
However, in eastern countries, particularly in Japan, the 
Okabayashi method is the standard procedure of radical 
hysterectomy. Both methods separate the anterior leaf of the 
vesico-uterine ligament, but there is a different concept on the 
separation of the posterior leaf of the vesicouterine ligament. 
The class III method divides the paravaginal tissues together 
with the posterior leaf of the vesicouterine ligament and the 
paracolpium (vaginal blood vessels). In contrast, the Okaba-
yashi method separates and divides the posterior leaf of the 
vesicouterine ligament intentionally and then the para-
colpium is isolated and divided, respectively. The latter proce-
dure enables the surgeon to separate the bladder with the ure-
ter completely away from the lateral side of the cervix and vag-
ina and allows easy resection of any vaginal length deemed ap-
propriate for the optimization of the radical hysterectomy. 
However, both types of radical hysterectomy have been often 
associated with severe bladder dysfunction and colorectal mo-
tility disorders.
The uterus, vagina, urinary bladder, and rectum are in-
nervated by a motor and sensory autonomic nerve supply, 
both of sympathetic and parasympathetic origin. The sym-
pathetic fibers come from T11-L2 which forms the superior 
hypogastric plexus. The parasympathetic fibers come from 
S2, 3, and 4 at the pelvic wall as the pelvic splanchnic nerve. 
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These fibers merge and form the inferior hypogastric plexus 
which branch to innvervate the uterus and the urinary 
bladder. It has been reported that during radical hysterectomy 
the hypogastric nerve is often sacrificed when the surgeon di-
vides the uterosacral ligament and rectovaginal ligament, the 
pelvic splanchnic nerve when the surgeon divides the deep 
uterine vein in the cardinal ligament, and the bladder branch 
of the pelvic nerves when the surgeon ligates and divides the 
paracolpium.38
However, the anatomy of the inferior hypogastric plexus en-
compassing the hypogastric nerve, the pelvic splanchnic nerve 
and the bladder branch/the uterine branch from this plexus is 
complicated and is not easy to appreciate during the surgery. 
In order to accomplish nerve-sparing radical hysterectomy, it 
is absolutely necessary for us to reveal the inferior hypogastric 
plexus and to transect only the uterine branch from the in-
ferior hypogastric plexus. By this procedure we can preserve 
the hypogastric nerve, the pelvic splanchnic nerve and the 
bladder branch from the inferior hypogastric plexus.
We have recently reported how to identify the inferior hypo-
gastric plexus.22,38 As well as these papers, the paper on the 
anatomy of the vesico-uterine ligament (anterior/posterior) 
that we previously published shall be helpful for the under-
standing of the whole anatomy of the inferior hypogastric 
plexus.
2. Optimal staging in early ovarian cancer, Dae Gy Hong/ 
Yoon Soon Lee
The primary treatment for early stage epithelial ovarian can-
cer is surgical, and patients should undergo total abdominal 
hysterectomy, bilateral salpingo-oophorectomy, and surgical 
staging. Fertility preservation operation in early stage ovarian 
cancer is recommended for patients who have undergone a 
through staging operation and for whom there is no evidence 
of spread beyond the ovary, otherwise abdominal hyster-
ectomy and bilateral salpingo-oophorectomy are appropriate 
therapy.39
The uterus and the contralateral ovary can be preserved in 
women with stage Ia, grade 1 to 2 disease who desire to pre-
serve fertility. For patients whose disease is more poorly dif-
ferentiated or in whom there are malignant cells either in as-
citic fluid or in peritoneal washings, complete surgical staging 
must be performed. 
Despite the prognostic relevance of lymph node metastasis, 
there is a great debate about the role of pelvic and para-aortic 
lymph node dissection.40 In early ovarian cancer, lymph node 
dissection is required to make an accurate clinical stage ac-
cording to the FIGO classification and to select adequate ad-
juvant therapy. But the survival benefit of pelvic and 
para-aortic lymph node dissection in early ovarian cancer is 
controversial. 
There have been no randomized trials published to date to 
compare the laparoscopic surgical staging of presumed early 
ovarian cancer with conventional open staging. Now, the fea-
sibility and safety of laparoscopic staging early ovarian carci-
noma have been established.41 The tumor control and survival 
of minimal access surgery in early ovarian cancer have not 
been compared with conventional open procedures by 
randomized study. Impaired survival compared with conven-
tional open treatment has not been demonstrated for any lap-
aroscopically treated malignancy.42
Although ongoing surveillance, attention to technique, and 
appropriate management of port sites are mandatory, the lap-
aroscopic management of early ovarian cancer seems to be 
justified by the significant reduction in morbidity, hospital 
stay, and recovery time that result from this surgical approach 
and by lack of any solid evidence that if used properly by quali-
fied individuals it does not harm.42 
In conclusion, primary surgical staging is the standard pro-
cedure in early ovarian cancer but some considerations must 
be given to the variable situations. Although laparoscopic 
staging for ovarian cancer is controversial, it may be an alter-
native approach for early ovarian cancer.
3. Laparoscopic radical hysterectomy, Jong Hyeok Kim
Laparoscopic surgery has many benefits over conventional 
abdominal approach. These include less postoperative pain, 
improved cosmetics, less blood loss, shorter recovery time, 
shorter length of hospital stay, and shorter time interval to ad-
juvant therapy without increase in complications or morbi-
dity. In addition, it appears that the risk of cancer recurrence 
does not increase with a laparoscopic approach. With ad-
vances of laparoscopic instruments and surgical skills, laparo-
scopic surgery also has been adopted in the surgical manage-
ment of early cervical cancers. 
Laparoscopic radical hysterectomy (LRH) for the treatment 
of patients with early cervical cancer was first described in the 
early 1990s, but the acceptance of LRH has been slower than 
other laparoscopic oncologic surgical techniques and the use 
of LRH was limited to the patients with small tumor because 
of its technical difficulty and diversity of surgical techniques.
However, with increasing experience, standardization of 
technique, and advances of laparoscopic instruments, the in-
dication of LRH is extending to almost all patients with early 
cervical cancer, and LRH is becoming a dominant paradigm in 
the surgical management of early cervical cancer.43 According 
to the currently existing data in the literature reported by sev-
eral expert surgical teams through the world, there is no 
doubt that LRH is feasible and safe both surgically and 
oncologically.44 The rate of conversion to laparotomy was ex-
tremely low and the surgical safety profile was comparable to 
that of abdominal radical hysterectomy (ARH). The surgical 
outcomes were even more favorable in terms of operating 
time, estimated blood loss, transfusion requirement, post-
operative complication rate, postoperative recovery, cosmetic 
results, and patients’ satisfaction. The local radicality and 
lymph node yield were also similar to those of ARH, and the 
recurrence rate and survival rate after LRH were also equiv-
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alent to those of ARH. Although the best way to evaluate the 
feasibility and safety of LRH is to compare LRH with ARH in 
a randomized controlled trial (RCT), such a study is nearly 
impossible nowadays because patients will refuse to partic-
ipate in the study if they were randomized to the open surgery 
group. Many gynecologic oncologic surgeons believe that 
LRH can be safely performed in almost all patients with early 
cervical cancer without decrease in survival of patients, and 
the surgical outcomes are superior to conventional open sur-
gery if the surgery is performed by an experienced laparo-
scopic surgical team.45
During the last 13 years, LRH has been performed in over 
500 patients with early cervical cancer in our department. We 
have found that the surgical and oncologic outcomes were 
similar or even better compared to ARH. We strongly believe 
that laparoscopic surgery should be the preferred standard 
surgical management for early cervical cancer, and gyneco-
logic oncologic surgeons should do their best to improve lapa-
roscopic surgical techniques. 
4. One-port surgery, Tae-Joong Kim
Single-port access (SPA) laparoscopic surgery is evolving as 
new instruments become available. The advantages over tra-
ditional multi-port laparoscopic surgery with regard to mor-
bidity, good cosmetic results and less postoperative pain are 
documented,46 but these advantages should be evaluated in 
well-designed prospective trials. There are some published re-
ports of SPA laparoscopy utilized to treat benign gynecologic 
disorders.47
However, there are few reports on the use of SPA laparo-
scopy in gynecologic cancers. For now, SPA is considered for 
risk-reducing salpingo-oophorectomy, total hysterectomy for 
precancerous lesions, and staging operation for early stage 
ovarian/endometrial cancer. Fader et al. reported the feasi-
bility of SPA in treating a variety of disease processes.48 Of 
thirteen patients who had SPA surgery performed, 9 were 
done laparoscopically and four robotically. Procedures in-
cluded endometrial cancer staging (n=1), ovarian cancer 
staging (n=1), retroperitoneal pelvic lymph node dissection 
(PLND, n=1), risk-reducing extrafascial hysterectomy/bi-
lateral salpingo-oophorectomy (BSO, n=2) and BSO alone 
(n=5), and an ovarian cystectomy (n=1) and BSO (n=2) for 
complex adnexal masses. All procedures were successfully 
performed via a single incision and no post-operative compli-
cations occurred. 
We have two cases of SPA laparoscopic staging operations in 
the video clips - one was BSO, laparoscopy-assisted vaginal 
hysterectomy (LAVH), bilateral PLND, infracolic omentec-
tomy, and washing cytology in borderline ovarian tumor, and 
the other was LAVH, BSO, PLND with washing cytology in 
endometrial cancer (video clip available at the ASGO home-
page). The number of harvested pelvic lymph nodes were 23 
and 19, respectively, and there were no intraoperative or post-
operative complications. SPA laparoscopic staging may be 
performed in selected patients. The efficacy, safety, and po-
tential benefits of this technique should be evaluated in fur-
ther trial.
5. Robotic surgery, Young Tae Kim
Operative laparoscopy was initially developed in the field of 
gynecology earlier on and the advent of laparoscopic surgery 
led to advances in general surgery as well. In the last few years, 
a number of articles have been published on the performance 
of surgical procedures using the robot-assisted laparos-
copy.49-51 The shortcomings of conventional laparoscopy have 
led to the development of a robotic surgical system and the fu-
ture of telerobotic surgery is not far away, enabling a surgeon 
to operate at a distance from the operating table. 
The complete loss of tactile sensation is often quoted as a big 
disadvantage of working with robotic systems. Although the 
first generation da Vinci Robotic surgical system provided im-
proved imaging and instrumentation, the absence of tactile 
feedback and the high cost of the technology remain as 
limitations. New generations of robotic surgical systems have 
been developed, allowing visualization of preoperative imag-
ing during the operation. Though the introduction of robotics 
is very recent, the potential for robotics in several specialties 
is significant. However, the benefit to patients must be care-
fully evaluated and proven before this technology can become 
widely accepted in the gynecologic surgery.
ENDOMETRIAL CANCER
1. Laparoscopic surgery versus open surgery in endometrial 
cancer, Kung-Liahng Wang
Surgery has been the primary treatment of choice for endo-
metrial cancer since the adaptation of FIGO surgical staging in 
1988. However, the extent of operation depends not only on 
various disease characteristics, but also on the surgeon’s spe-
cialties as well as the guideline of respective institutes. Several 
issues still remain to be clarified, including the option of radi-
cal hysterectomy,52 feasibility of ovarian preservation53 and 
the necessity of high para-aortic lymph node dissection.54 
Alternatively, laparoscopic management of gynecologic ma-
lignancy has received much attention and given rise to consid-
erable debates in the past decade.44,55,56 Of these tumors, early 
endometrial cancer is probably the one with the least concern 
in terms of technical feasibility and disease spreading pattern. 
The advantages of laparoscopy have been well documented in 
lessening the morbidity of laparotomy, providing better visu-
alization for delicate tissue dissection of lymph nodes, and ex-
pediting the post-operative recovery of the patients. On the 
other hand, important considerations such as the expertise of 
the surgeon, impact of positive peritoneal cytology by laparo-
scopy, and its performance in obese patients might limit the 
routine use of this procedure in endometrial cancer.57
The results of several clinical trials and retrospective studies 
unanimously demonstrated the safety, effectiveness and 
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short-term advantages of laparoscopy over laparotomy. A 
large Gynecologic Oncology Group (GOG) LAP2 phase III 
randomized study comparing laparoscopy versus laparotomy 
in endometrial cancer revealed that laparoscopic surgical 
staging could be performed in 76.3% of cases.58 Quality of life 
and physical functioning were significantly improved 6 weeks 
post-operatively following laparoscopy. The estimated 3-year 
overall survivals were 89.8% and 89.9% for patients random-
ized to laparoscopy and laparotomy, respectively. It concluded 
that laparoscopic surgical staging for uterine cancer does not 
result in an inferior outcome for recurrence or survival; and 
should be considered as a standard of care for endometrial 
cancer. Another large randomized trial “Laparoscopic Approach 
to Cancer of the Endometrium (LACE)001” is still ongoing. 
Meta-analysis of four other RCT showed that longer operative 
time, lower intra-operative blood loss, and fewer post-oper-
ative complications were associated with laparoscopy, when 
comparing to laparotomy. There are no differences in the 
overall, progression-free and cancer-related survivals.59
Until mature data from the LACE trial become available and 
demonstrate otherwise, the application of laparoscopic surgi-
cal staging operation is considered a good alternative to lapa-
rotomy for endometrial cancer.
2. Role of lymphadenectomy in endometrial cancer, Taek 
Sang Lee
The lack of consensus for primary surgical treatment of en-
dometrial cancer, the most common gynecological cancer, is 
deplorable. Whether lymphadenectomy should be done to-
gether with hysterectomy has been debated at length and 
passionately. To avoid unnecessary lymph node (LN) dis-
section and related surgical morbidity, imaging modalities 
have been suggested for prediction of LN metastasis.60 
Sensitivity and negative predictive value of MRI for LN meta-
stasis were reported as 45% to 78% and 91% to 95%, respec-
tively. Because of this uncertainty, MRI does not seem to be 
able to replace surgical staging in the prediction of LN 
metastasis. 
Additionally, LN metastasis is highly correlated with the 
depth of myometrial invasion (MMI), and prediction of MMI 
is crucial in decisions as to whether conservative treatment 
should be administered to uterine corpus cancer patients. 
However, the sensitivity (36% to 90%) and negative pre-
dictive value (83% to 94%) of MRI in the detection of deep 
myometrial invasion was not satisfactory. 
In 1987, Creasman et al.61 reported a large scaled study of the 
patterns of spread in endometrial cancer. This study in-
troduced the concept of surgical staging and specific factors 
including tumor grade, depth of myometrial invasion, lym-
phovascular space invasion (LVSI), positive peritoneal cytol-
ogy, adnexal involvement, and other evidence of extra-uterine 
disease to predict for nodal metastases. 
Trimble et al.62 addressed survival in 9,185 endometrial can-
cer patients in the National Cancer Institute Surveillance, 
Epidemiology and End Results program (SEER) database. 
They compared patients who did and did not undergo lympha-
denectomy at surgery. For stage I endometrial cancer, 5-year 
survival was not significantly different between the two 
groups. It was only in grade 3 patients that there was a sig-
nificant survival difference in favor of lymphadenectomy 
(0.89 vs. 0.81, P¼0.011). 
The recently published ASTEC surgical trial randomized just 
over 1400 women with endometrial carcinoma, preoperatively 
thought to be confined to the uterine corpus, and asserted that 
routine systematic lymphadenectomy was not recommended 
for therapeutic purposes in patients with stage I disease. 
However, The negative results from this trial was criticized in 
some points that all histologic subtypes were included, 
para-aortic LN dissection was optional and inconsistently 
harvested, an inadequate number of LNs was retrieved in 1/3 
of patients, and most patients were in the low-risk group.63 
Recently, Todo et al.64 reported in SEPAL study that the addi-
tion of paraaortic lymphadenectomy to hysterectomy and pel-
vic lymphadenectomy reduced the risk of death, with a hazard 
ratio of 0.44 (95% CI, 0.30 to 0.64; p＜0.0001).64
A Korean multi-center retrospective study involving 758 pa-
tients surgically treated for early-stage endometrioid uterine 
cancer, with a median follow-up of 35 months, reported that 
systematic lymphadenectomy did not provide a therapeutic 
benefit in terms of overall survival in all of the patients, while 
overall survival improved only in high-risk patients.
Therefore, we suggest that systematic lymphadenectomy is 
effective in detecting micro or occult LN metastasis, and thus 
improve surgical staging and make it possible to accurately 
predict the prognosis at least in patients with high risk uterine 
corpus cancer. The greatest challenge should be continued to 
define and accurately detect low-risk disease.
3. Fertility sparing treatment for endometrial cancer, Kimio 
Ushijima
As the number of younger women with endometrial carcino-
ma has increased, fertility-sparing treatment has received 
much attention.53,65 Progestin has played a major role in this 
treatment. Nevertheless, the clinical benefit of fertility spar-
ing treatment with progestin is still uncertain. To clarify the 
efficacy of fertility-sparing treatment using medroxyproges-
terone acetate (MPA) for endometrial carcinoma (EC) and 
atypical hyperplasia (AH) in young women, we conducted a 
multicenter prospective study for this issue at 16 institutions 
in Japan.66
Twenty-eight patients having EC at presumed stage Ia and 
17 patients with AH at less than 40 years of age were enrolled. 
All patients were given a daily oral dose of 600 mg MPA with 
low dose aspirin. This treatment continued for 26 weeks, as 
long as the patients responded. Either estrogen-progestin 
therapy or fertility treatment was provided for the responders 
after MPA therapy. Complete response (CR) was found in 
55% of EC cases and 82% of AH cases. The overall CR rate was 
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67%. Neither therapeutic death nor irreversible toxicities 
were observed. During the 5-year follow-up period, among 20 
patients hoping to conceive a child, fifteen pregnancies in 12 
patients and 9 normal deliveries were achieved after MPA 
therapy. Eleven of 15 pregnancies were brought about by fer-
tility treatment, and 8 of them were achieved by in-vitro fertil-
ization and embryo-transfer program. Fifteen recurrences 
were found between 7 and 58 months including 9 of 14 EC 
(64%) and 6 of 16 AH (38%). Recurrence was seen in 72% of 
patients having a treatment free period and in 86% of patients 
without conception in spite of fertility treatment.
Four cases of ovarian malignancies (10.2%) were found in 
this study. In EC patients at our institution, there was a higher 
incidence of ovarian cancer in EC patients of less than 40 years 
of age (15.0%) than in patients more than 40 years of age 
(6.6%). Also, a high incidence of clonality difference between 
endometrial cancer tissue and ovarian cancer tissue was found 
in younger patients.
In conclusion, the efficacy of fertility-sparing treatment by 
high- dose MPA for EC and AH has been proven by this first 
prospective trial. The indication of MPA therapy should be re-
stricted to stage 1a disease. Even in responders, close follow 
up with continuous Estrogen-Progesterone administration or 
immediate infertility treatment is required due to the sub-
stantial recurrence rate. Longer-term hormonal treatment or 
ovarian preservation at hysterectomy is not recommended, 
because these patients have a high incidence of synchronous 
ovarian cancer. Close communication and collaboration be-
tween the gynecologic oncologist and the reproductive endo-
crinologist is indispensable for patient safety and goal ach-
ievement in fertility-sparing treatment.
CLINICAL TRIALS IN ASIA
1. Asian role in global clinical drug development, Sang-Goo 
Shin 
Asia has been globalized in clinical trials just since the 
International Conference of Harmonization (ICH) started in 
early 1990s. Few Southeast Asian countries appeared to be in-
volved in the US initiated multinational trials during the 
mid-1990s. However, after consolidation of ICH-E5 (Ethnic 
factors in the acceptability of foreign clinical data) and ICH-E6 
(Good Clinical Practice) guidelines, many Asian countries 
started to change their drug regulatory environment to be 
compatible with western countries. From late 1990s to early 
2000s, several northeast Asian countries have been eager to 
participate in the global trial, but far later than east European 
and South American countries. In spite of their late harmo-
nization in drug regulations and trial environments, several 
Asian countries have been recognized for excellence in clinical 
trial activity, especially in the late phases with their large 
treatment-naive patient populations and relatively low study 
cost with a track record of faster patient recruitment.
According to a November 25, 2009 analysis by PAREXEL con-
sulting and KoNECT, East Asian countries (Korea, Taiwan, 
China, Hong Kong, and Japan) were participating in 15.7% of 
all phase III clinical trials listed in the www.clinicaltrials.gov 
database in 2008 and 18.2% in 20091H, up from just 9.6% in 
2005. Meanwhile, the region has seen a number of phase III cli-
nical trials in which it is participating (again listed in 
clinicaltrials.gov) surge by 30.9% from 2005 to 2008. However 
early phase research in Asia has been fairly limited, and mainly 
consists of bridging studies providing local pharmacokinetics, 
pharmacodynamics, efficacy and safety data for registration of 
foreign-developed drugs in each country.
Recently, a new trend has emerged especially among large 
companies such as Pfizer and GSK, who are conducting global 
trials, with more and more Asian sites starting to be involved 
in early-phase studies. This trend is the result of increased 
confidence in quality and speed in Asian sites that have been 
built through late phase clinical trials in the region, especially 
in Singapore, South Korea, and Taiwan, including Japan. 
There are many sites with excellent facilities suitable for early 
proof of concept studies including phase 1 studies for normal 
volunteer or patient-based PK-PD studies, with trained clin-
ical research personnel including clinical pharmacologists 
and experienced clinical investigators. In 2008, around 35% 
out of 216 multinational trials approved by Korean Food & 
Drug Administration (KFDA) were early phases clinical trials. 
That was the result of government initiatives to foster a clin-
ical trial infrastructure including Regional Clinical Research 
Centers and the collaboration among government, academia, 
and industry. Singapore has a very small population, which is 
not suitable for large scale clinical trials, but it is attracting 
lots of international interest in the early phase research, be-
cause the country's Biomedical Sciences initiative has been 
encouraging, and is enabling international companies to set 
up dedicated Phase I centers in Singapore and Korea. Early 
phase clinical research in Asian Region can also reduce the 
drug-lag for patient access to new innovative drugs and phase 
lag in clinical development in the region. For pharmaceutical 
companies, it increases market access to the huge Asia mar-
kets including South Korea, China, and especially Japan.
However, there are still challenges in this region in conduct-
ing early phase trials which include slow clinical trial author-
ization and lack of public awareness of early phase clinical 
trials.
This presentation will highlight past historical experience of 
globalization and current status of clinical trials, especially in 
northeast Asian countries, and will also discuss the oppor-
tunities and challenges of Asian countries in simultaneous 
global trials environment.
OVARIAN CANCER
1. First line chemotherapy: overview of trends, Yin Nin 
Chia
The accidental discovery of Melphan as a chemotherapeutic 
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agent during World War II has revolutionized the treatment 
of epithelial ovarian cancers. Since then, many new chemo-
therapeutic agents have emerged and have dramatically im-
proved the survival of an otherwise fatal disease. In the 1990s, 
the discovery of platinum was a great milestone forward in 
further improving the outcome. By the late 1990s and early 
2000s, the combination of platinum and taxane has become 
the new standard of care in the first line management of epi-
thelial ovarian cancers. 
In recent years, attempts have been made both in terms of 
new agents as well as the route/dose of administration to fur-
ther improve upon this current standard. Docetaxel may be 
considered as an alternative to paclitaxel in those in whom pe-
ripheral neuropathy is a concern. GOG 172 trial of IP-IV che-
motherapy in 2006 found an impressive improvement in me-
dian overall survival of 16 months resulting in a NCI alert in 
2006 to support a first line regimen containing IP cisplatin 
and IV/IP taxane in women with optimally debulked stage III 
epithelial ovarian cancers.67 
The Japanese GOG in a recently published a RCT in Lancet 
2009 showed an improvement in overall progression free sur-
vival (PFS) with dose dense chemotherapy using weekly pacli-
taxel in combination with 3 weekly platinum ie, 28.0 months 
versus 17.2 months in the traditional 3 weekly regimen.68 
Most recently, a phase III trial by GOG of Bevacizumab pre-
sented in American Society of Clinical Oncology (ASCO) 2010 
showed a PFS of 14.1 months (carbo/paclitaxol/bevacizumab
＋maintenance bevaxizumb versus 11.2 months (carbo/pacli-
taxol/bevacizumab) versus 10.3 months (control arm car-
bo/paclitaxol only). Recognizing that epithelial ovarian can-
cers are a heterogeneous group of diseases, there is also a 
trend towards immunotherapy in the management of epi-
thelial ovarian cancers.
2. Neo-adjuvant chemotherapy (NACT) in ovarian cancer, 
Sarikapan Wilailak
Bulky scattered disease in difficult sites precludes optimal cyto-
reductive surgery. With regard to chemotherapy, ovarian cancer 
is moderately sensitive to chemotherapy, and it is difficult for 
bulky disease to be completely diminished by chemotherapy.
NACT is the administration of cytotoxic chemotherapy be-
fore attempting aggressive cytoreductive surgery for treating 
women with advanced-stage epithelial ovarian cancer.69 This 
approach was first used at Yale University in 1979. The diag-
nosis of ovarian cancer was based on cytologic or histologic 
specimens and diagnostic imaging findings consistent with 
ovarian cancer. The initial approach used at Yale University 
was to reserve NACT for patients who were too medically in-
firmed to tolerate aggressive cytoreductive surgery. A decade 
after its use in that regard, NACT was then offered to the pa-
tients who, by CT criteria, were unlikely to be optimally surgi-
cally cytoreduced. 
A meta-analysis of Bristow et al.70 which included 6,885 pa-
tients with stages III and IV ovarian cancer, reported an opti-
mal cytoreduction rate (＜2 cm residual disease) of 42%. 
Also, only a small fraction of patients were cytoreduced to mi-
croscopic disease. A recent GOG study reported that only 23% 
of 1,895 stage III patients and only 8% of 360 stage IV patients 
were cytoreduced to microscopic disease.71 One of the most 
important prognostic factors of ovarian cancer is residual dis-
ease after surgery. Therefore, to reduce residual disease after 
surgery to the level of ＜1 cm or no gross residual is vital. 
NACT would be beneficial in terms of having patients in a bet-
ter preoperative status (ie, nutritional status, ascites, pleural 
effusion), having a higher rate of surgical cytoreduction to no 
visible disease, and less operative morbidity including shorter 
time, less blood loss, and shorter hospitalization.
To date, two meta-analyses have been published.72,73 The first 
in 2006 by Bristow and Chi72 reviewed 22 cohorts of patients 
with stages III and IV ovarian cancer (835 patients) who re-
ceived NACT with a platinum-based regimen prior to surgery. 
The authors concluded that NACT survival outcomes are over-
all infusion compared to conventional primary surgery. More 
recently in 2009, Kang and Nam73 performed a meta-analysis 
using a random-effects model to perform statistical analysis 
that accounts for the sample heterogenicity and retrospective 
nature of the studies in order to obtain more reliable results. 
Twenty one studies were reviewed. Their results agree with 
Bristow et al. in that NACT affords greater optimal cytor-
eduction rates. Interestingly, they found a trend for increased 
median overall survival in the NACT group. However, this was 
not significant.
Only one well controlled randomized trial comparing NACT 
with primary cytoreductive surgery has been completed and 
two trials are currently underway. The European Organisation 
for Research and Treatment of Cancer (EORTC) completed 
randomized trial of 718 patients revealed the same over-all sur-
vival, whereas the complication rates were higher in the primary 
cytoreductive group. In the United Kingdom, recruiting pa-
tients for a trial of chemotherapy or upfront surgery (CHORUS) 
is underway, with a goal of 550 patients. Lastly, the Japanese 
Clinical Oncology Group (JCOG) is randomizing 300 patients 
to either the NACT or primary cytoreductive arm.
NACT followed by surgery is best suited for patients with med-
ical co-morbidities not able to undergo aggressive cytoreduc-
tive surgeries, and for patients deemed to have unresectable 
disease. However, the ability to predict unresectable disease re-
mains limited and this in itself remains a major factor in select-
ing patients who would be appropriate candidates for NACT. 
The proper number of cycles given prior to surgery is to be 
defined. Significant benefits of NACT will be lost if the patient 
is not operated on promptly or if less than optimal surgical cy-
toreduction is performed. 
3. Optimal surgical management for ovarian cancer, Sang 
Yoon Park
Among several prognostic factors, postoperative residual tu-
mor size is the only changeable factor when physicians man-
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age the patients. We should keep in mind that the morbidity 
of surgery should not interrupt postoperative adjuvant che-
motherapy because chemosensitivity is one of the most im-
portant prognostic factors.
Not only advanced ovarian cancer but also early ovarian can-
cer is confirmed after pathologic examination from extensive 
surgery in the current FIGO staging system: hysterectomy, 
BSO, omentectomy, lymph node dissection, peritoneal biop-
sy, and washing cytology are essential surgical procedures for 
optimal staging. In early ovarian cancer, unique character-
istics, such as a higher incidence of non-serous histology and 
co-existence of endometriosis, have been identified. Ovarian 
carcinogenesis from endometriosis has been reported.74 
Endometriosis mimics ovarian cancer clinically. Complete ex-
cision of suspicious lesion for endometriosis or ovarian cancer 
may be important in the surgical management of ovarian can-
cer because intra-operative differentiation of endometriosis 
from ovarian cancer is difficult. 
Advanced epithelial ovarian cancer typically presents with 
widely disseminated intra-abdominal disease. The standard 
treatment of advanced epithelial ovarian cancer (EOC) in-
cludes primary cytoreductive surgery followed by adjuvant sys-
temic chemotherapy. The goal of primary surgery for advanced 
EOC is to accurately establish a diagnosis and leave little or no 
residual disease. Although there are no RCT supporting cyto-
reductive surgery, nearly every retrospective and prospective 
study has demonstrated an inverse relationship between re-
sidual tumor diameter and patient survival.75 
A substantial number of patients with advanced-stage ovar-
ian cancer present with bulky upper abdominal disease, ma-
lignant pleural effusions, or even intraparenchymal liver dis-
ease, and may require diaphragmatic or intestinal procedures, 
splenectomy with/without a distal pancreatectomy, and peri-
toneal stripping to achieve an optimal cytoreduction. Recent 
data demonstrate the technical feasibility of ultra-radical sur-
gery and the significant survival advantage afforded by opti-
mal tumor removal even in stage IV patients. 
Surgery for ovarian cancer requires that the abdominal in-
cision be adequate to explore the entire abdominal cavity and 
allow safe cytoreductive surgery. Any ascites or free peri-
toneal fluid should be collected for cytology. If no free peri-
toneal fluid is present, separate peritoneal washings can be 
obtained from the pelvis, paracolic gutters, and infradia-
phragmatic area. Patients with stage III or IV disease do not 
require cytologic assessment. All peritoneal surfaces includ-
ing the surface of both diaphragms and the serosa and mesen-
tery of the entire gastrointestinal tract should be visualized 
and palpated for evidence of metastatic disease with careful 
inspection of the omentum and removal, if possible.
In addition to conventional optimal staging surgery, splenec-
tomy, distal pancreatectomy, liver resection, resection of tu-
mor from the porta hepatis, cholecystectomy, total colectomy, 
pelvic peritonectomy, diaphragmatic stripping and/or re-
section should be tried to attain minimum residual disease as 
an extensive surgery. Sometimes video assisted thoracosocpic 
surgery (VATS), wedge resection of the stomach, pelvic bone 
resection, and abdominal wall resection may be needed. 
Although clinical CR can be achieved in many patients with 
advanced EOC using a combination of cytoreductive surgery 
and chemotherapy, the disease will likely recur and require 
further intervention. Complete resection of the tumor re-
currence was one of the most powerful determinants of pro-
longed survival. Surgery for recurrent EOC should therefore 
be considered for patients with a localized recurrence, an ex-
tended disease-free interval of at least 6 to 12 months, and a 
good performance status. The resection of isolated hepatic 
and extra-abdominal disease such as solitary lung or central 
nervous system (CNS) lesions also seems to afford a similar 
survival advantage for the affected patients. 
4. Research targets in targeted therapy, Hidetaka Katabuchi
While advances in chemotherapy have certainly improved 
the prognosis for ovarian cancer patients, survival rates and 
the long-term prognosis remains poor. Current clinical man-
agement of ovarian cancer exists against a background of in-
sufficient information regarding precursor cells, risk factors, 
and the mechanisms of carcinogenesis and dissemination. 
Recently, clinical trials of chemotherapy combined with mo-
lecular targets developed for other diseases, particularly anti-
angiogenic drugs, have been conducted to ovarian cancer, but 
the anticipated results have not always been obtained. In this 
lecture, we extracted keywords from ovarian cancer research 
and, based on these as starting points, discuss the outlook for 
the development of novel therapeutic strategies for ovarian 
cancer.
The precursor cells of ovarian cancer have not yet been iden-
tified, and one of the major reasons underlying the dismal 
prognosis of this disease is that nearly 75% of cases are al-
ready at an advanced stage at diagnosis. Moreover, each of the 
four main cancer tissue types, serous, mucinous, endome-
trioid and clear cell adenocarcinoma, has different clinical fea-
tures and, thus, the precursor cell type may be different for 
each of these tissues. Among the potential precursor cell 
types, ovarian surface epithelium and inclusion cysts are the 
most likely candidates.76,77 One basis for this supposition is 
the existence of de novo ovarian cancer, which is common 
among serous adenocarcinomas. For serous tissue types, we 
should also mention the adenoma-carcinoma sequence pro-
gressing from an adenoma/borderline malignancy through a 
micropapillary variant to a carcinoma. Furthermore, recent 
studies of women with BRCA1/2 mutations undergoing risk- 
reducing salpingo-oophorectomy have highlighted the distal 
fallopian tube as a common (80%) site of tumor origin. 
Additional studies of unselected women with pelvic serous 
carcinoma have demonstrated that serous tubal intraepithelial 
carcinoma may precede a significant percentage of these pel-
vic tumors. On the other hand, in some mucinous, endome-
trioid, and clear cell adenocarcinomas, there is a process of 
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malignant alteration of the respective benign adenoma or of 
endometriosis. Among these malignant alterations are bor-
derline malignancy and atypical endometriosis.
Epidemiology provides an important basis for considering 
cancer risk factors. Human papilloma virus in cervical cancer 
and estrogens in endometrial cancer are classic examples of 
cancer risk factors. The development of ovarian cancer is in-
fluenced by lifetime ovulation frequency and incessant ov-
ulation is still considered a leading risk factor.76 Meanwhile, 
the peak age for ovarian cancer corresponds to the physiologic 
rise in pituitary gonadotropins seen during perimenopause 
and the prevalent expression of gonadotropin receptors by 
many ovarian cancers suggests that these hormones are an im-
portant factor in carcinogenesis. The possible connection be-
tween chemical substances, such as talc, and cancer also re-
quires further attention as the peritoneal cavity of women is 
linked to the external environment via the fallopian tubes, and 
the incidence of ovarian cancer is high in advanced countries, 
which tend to have higher levels of environmental pollution.
With the discovery of the BRCA1/2 gene in the breast-ovar-
ian cancer syndrome, and the abnormal mismatched repair 
gene in the Lynch syndrome, a part of the ovarian cancer carci-
nogenesis process has also been clarified. Specific gene abnor-
malities in each type of ovarian cancer have also been identi-
fied, including KRAS in mucinous adenocarcinoma, PTEN and 
β-catenin in endometrioid adenocarcinoma, and KRAS in 
clear cell adenocarcinoma. Moreover, from studies of carcino-
genesis at the molecular level, serous adenocarcinomas have 
been classified as low-grade based on BRAF and KRAS abnor-
malities and as high-grade based on p53, HER2/neu, and AKT2 
abnormalities. 
In recent studies involving the transfer of abnormal candidate 
genes using immortalized ovarian surface epithelium,78-80 the 
tumor formation stage has been reached, but differentiation 
to ovarian cancer-specific tissue types has not been achieved. 
Further elucidation of ovarian cancer-specific precursor cells, 
risk factors, and the mechanisms of carcinogenesis is needed. 
Based on such findings, a change in our current perspective 
may pave the way for the development of novel treatments for 
ovarian cancer.
ADDENDUM
During break times, approaching meeting schedules and a 
few promotions of other societies were introduced. A promo-
tion slide of the ASGO online homepage was presented to en-
courage Asian gynecologic oncologists to sign up for the 
membership of the ASGO. In addition, the interim meeting of 
Asia Oceania research organisation on Genital Infections 
(AOGIN) scheduled for March 17-19, 2011 at Bali, Indonesia 
before the 5th biennial meeting of the year of 2012. On April 
2-3 of next year, the International Gynecologic Cancer Society 
(IGCS) regional meeting on gynecologic cancers will be held 
in New Delhi, India. Finally, the 2nd biennial meeting of 
ASGO will be held November 4-5, 2011 in Seoul, Korea.
Thanks to all the speakers, the slides and video clips are 
available at the ASGO homepage, asiansgo.org with permi-
ssions.
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